Navigation Links
Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
Date:10/7/2008

Vaccine Has Potential to Save Millions of Lives

GERMANTOWN, Md., Oct. 7 /PRNewswire/ -- Integrated BioTherapeutics Inc. (IBT), a biotechnology company focused on development of medical countermeasures for biodefense and emerging infectious diseases, announced they have been awarded a multiyear contract for advanced development of a vaccine to protect against Ebola and Marburg viruses from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The contract is valued at approximately $22 million, which, if options are exercised, could total up to $65 million.

Considered a significant bioterrorist threat, Ebola and Marburg lead to death 30-90 percent of the time they are contracted, and there are currently no vaccines or therapeutics available for treatment of humans infected with either virus. Ebola and Marburg virus outbreaks typically occur in resource poor areas in Sub-Saharan Africa, although rare cases have occurred in the United States, Europe and the Philippines. Filoviruses are also a source of concern as potential bioterror agents.

"We are very pleased that NIAID has awarded such a significant contract to fund the advanced development activities for our virus-like particle vaccine against Ebola and Marburg viruses. This is a significant step forward in our mission to improving public health and developing medical countermeasures for biodefense. This contract will fund a major portion of the preclinical and clinical activities required to confirm and refine the activity in animals and verify the activity in humans," commented Dr. Javad Aman, IBT President and Chief Scientific Officer.

IBT is collaborating with colleagues at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to develop a subunit vaccine, based on the virus-like particles, with broad-spectrum activity toward different strains of Ebola and Marburg viruses. Other col
'/>"/>

SOURCE Integrated BioTherapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Integrated Prevention Demonstration Campaign Launched in Western Kenya to Fight HIV, Malaria and Diarrhoeal Disease
2. WolfPAC(sm) Integrated Risk Management Announces 100th Sale
3. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
4. Chiltern Early Phase: Fully Integrated and Business Ready
5. Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area
6. A first in integrated nanowire sensor circuitry
7. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
8. Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution
9. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
10. Augusta Systems Technologies Integrated into Ciscos Newly Launched Safety and Security Platform
11. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Livermore, California (PRWEB) October 01, 2014 ... Reyes has assumed the 2014-15 chairmanship of the ... election as vice chair in 2012. , Reyes has ... projects. She joined LLNL in 2001 to pursue her ... analysis of inertial fusion energy power plant designs. Since ...
(Date:10/2/2014)... 02, 2014 Cystic fibrosis (CF) is ... and the gastrointestinal organs. In particular, very thick mucus ... is very difficult to clear, occludes the airways, and ... these patients frequently suffer from chronic biofilm infections, and ... a novel approach to treating the major challenges in ...
(Date:10/2/2014)... (PRWEB) October 02, 2014 IAL ... fourth edition of its report on the markets ... new edition examines the developments encountered in the ... both products. , Full Report With TOC ... the market trends driving the demand. The study ...
(Date:10/2/2014)... Lexington,Kentucky and Queens, New York (PRWEB) October 02, ... is pleased to announce funding received to ... pathway in Alzheimer’s disease. A grant award from ... Institute on Aging (NIA), National Institutes of Health ... as Novel AD Therapeutics." The company also received ...
Breaking Biology Technology:Susana Reyes Assumes Chair of American Nuclear Society Fusion Energy Division 2Synedgen to Present at North American Cystic Fibrosis Conference 2Synedgen to Present at North American Cystic Fibrosis Conference 3Global Overview of the Spray Polyurethane Foam (SPF) & One Component Foam (OCF) : Industry Analysis, Size, Share, Trends And Forecast Research Report by Researchmoz 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... a biotechnology company developing peptide therapeutics for metabolic diseases, ... as Chief Executive Officer. Dr. Gottesdiener joins Rhythm from ... President and Late-Stage Therapeutic Group Leader, with responsibility for ... and previously as head of early-stage clinical development programs. ...
... -- an open-source, web-based platform for data-intensive biomedical ... a "cloud computing" resource. A team of researchers ... and molecular biology at Penn State University; Kateryna ... State; and James Taylor from Emory University, developed ...
Cached Biology Technology:Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Rhythm Names Keith M. Gottesdiener Chief Executive Officer 2Galaxy DNA-analysis software is now available 'in the cloud' 2Galaxy DNA-analysis software is now available 'in the cloud' 3
(Date:10/2/2014)... , October 2, 2014 ... Event for payment, identification and mobility which is ... from 4 to 6 November 2014, is proud ... partnership with innovation agency FABERNOVEL.   ... this initiative is to support innovative businesses from ...
(Date:10/2/2014)... SHELTON, Conn. , Oct. 2, 2014 NXT-ID, ... focused on the growing mobile commerce market, announces the airings ... Money and Mad Money. The national ads resumed ... will air October 2 nd and October 3 rd ... The continuing ads that began airing on CNBC ...
(Date:10/2/2014)... CARTES SECURE CONNEXIONS 2014 Conference: A Step Ahead ... SECURE CONNEXIONS 2014 is being held at Paris Nord ... This 29 th  international meeting for the digital security ... together the global community of a constantly evolving sector. ... will set the pace for the event.   ...
Breaking Biology News(10 mins):CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 2CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 3CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 4CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 5CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 2CNBC Commercial Airings for Wocket Smart Wallet October 2nd and 3rd 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 2CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 4
... in Acta Obstetricia et Gynecologica Scandinavica , a ... and Gynecology, indicate that human error is the most ... monitoring, lack of clinical skills, and failure to obtain ... Norwegian compensation claims following birth asphyxia. In ...
... we wanted to count the number of people in a crowd, ... imprecise, or we could ask each person to pass through a ... for creating a "DNA reader" that is able to detect the ... with integrated graphene transistor. The DNA molecules are diluted in ...
... team has discovered a gene associated with a high ... may be an actual cause of this form of ... "Because asthma is a complex disease, with multiple ... asthma occurring between ages two and six," said co-lead ...
Cached Biology News:Human error most common cause of birth asphyxia 2Graphene nanoribbons for 'reading' DNA 2Novel gene variant found in severe childhood asthma 2
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Reactivity: Human...
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: